Press releases

Data from 7000 TAXUS patients showed substantial benefits in keeping arteries open and avoiding repeat procedures

Data presented to a panel of experts assembled by the FDA in response to concerns about the incidence of late stent thrombosis in drug-eluting stents

A live webcast and replay of the November 29 session will be available

Becker will be responsible for managing the Company's global government affairs function, as well as its corporate public policy and political action committee

Lower re-intervention rates for the TAXUS Stent in diabetic patients

LATITUDE Patient Management is the first and only remote monitoring system to provide clinicians with direct device data integration capability into GE's Centricity Electronic Medical Record (EMR)

A replay of the webcast of today's analyst meeting will be archived and available in the Investor Relations section of the Company's website

Important and growing diabetic patient subset accounts for more than one-quarter of all coronary interventional procedures in the United States

Technology serves as second-generation platform for Company's market-leading TAXUS® paclitaxel-eluting coronary stent system

Company to acquire EndoTex

Innovative technology makes Precision™ spinal cord stimulator accessible to more patients

Brennan comes to the position with over 10 years’ experience at Boston Scientific; will be responsible for all aspects of investor relations

A live webcast and replay of the November 6 presentations will be available at Boston Scientific's website

Thousands of heart failure patients are now eligible for additional pacing feature

Zelenkofske to lead development and implementation of pre- and post-market clinical strategy that supports Company's CRM technology and therapy portfolio

Positive results also reported for TAXUS Liberte stent direct stenting

Results were announced at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, in Washington, D.C.

Results also show statistically significant late stent thrombosis rate for Cypher® stent vs. bare-metal stent

Two-year results continue to evaluate long-term safety and efficacy

Multi-center registry to enroll 10,000 patients over two years

Study of 1,558 patients was designed to retrospectively compare one-year clinical outcomes in real-world practice

"In Q3 we were able to achieve results near the high end of our previously announced preliminary sales and earnings ranges," said Jim Tobin, President and CEO

Results to include new data on next-generation TAXUS® Liberte™ Stent System

MAPS trial demonstrates Company's commitment to understanding the efficacy and durability of endovascular therapies for the treatment of brain aneurysms

Boston Scientific Corporation (NYSE: BSX) announced today that the PROMUS™ Everolimus-Eluting Coronary Stent System has received CE Mark...